Reta
What Is Retatrutide?
Retatrutide, also known as LY3437943 and commonly marketed in research settings as GLP-3R, is an investigational triple-receptor agonist studied for its interaction with three major metabolic hormone receptors: GLP-1, GIP, and glucagon.
Unlike single-pathway peptide compounds, retatrutide is designed to engage multiple metabolic signaling systems at the same time. In laboratory, preclinical, and controlled clinical research settings, it is examined for its relationship with glucose regulation, insulin-signaling pathways, lipid metabolism, energy balance, endocrine communication, and integrated metabolic control.
Because it targets GLP-1, GIP, and glucagon receptor pathways together, retatrutide is of strong interest in research models focused on metabolic regulation, body-composition signaling, hepatic lipid biology, insulin sensitivity, and systemic energy balance.
Certificate of Analysis
Third-party testing documentation available for purity and analytical verification.
GLP-3R / Retatrutide Research Overview
GLP-3R, also known as Retatrutide, is a synthetic peptide research compound designed to activate GLP-1, GIP, and glucagon receptor pathways.
GLP-1 receptor signaling is commonly studied for its connection to glucose-dependent insulin secretion, appetite-related signaling, gastric-emptying models, and metabolic regulation.
GIP receptor signaling is studied for its role in incretin biology, insulin response, adipose-tissue signaling, and nutrient-handling pathways.
Glucagon receptor signaling is studied for its relationship with hepatic metabolism, lipid utilization, energy expenditure, and metabolic flexibility.
By combining these three pathways into a single molecule, retatrutide provides researchers with a multi-receptor model for studying how incretin and glucagon signaling may interact across metabolic, endocrine, hepatic, and systemic research systems.
History and Development
The development of retatrutide builds on decades of incretin and metabolic hormone research.
Early GLP-1 receptor agonist research established the importance of GLP-1 signaling in glucose homeostasis, insulin response, and appetite-related metabolic pathways. Later research expanded into dual-receptor agonists, including GLP-1/GIP compounds, to study whether multiple incretin pathways could produce broader metabolic effects.
Retatrutide represents a further evolution of this field by combining GLP-1, GIP, and glucagon receptor activity into one investigational peptide. This triple-agonist design reflects growing scientific interest in studying integrated metabolic regulation rather than isolated hormone pathways.
In research literature, retatrutide is also known as LY3437943. It has been evaluated in preclinical studies, phase 1 studies, phase 2 clinical research, and ongoing later-stage development programs.
Retatrutide Profile
Retatrutide Structure
Research Findings
Retatrutide has been studied across metabolic, endocrine, hepatic, cardiovascular, and systemic research models. The main research interest centers on its ability to activate three hormone receptor pathways that are closely involved in metabolic regulation.
Key Areas of Investigation
- Metabolic Research: Glucose regulation, insulin sensitivity models, glycemic control pathways, nutrient utilization, and energy-balance signaling.
- Endocrine Research: GLP-1 receptor activity, GIP receptor activity, glucagon receptor activity, incretin biology, and multi-hormone communication.
- Hepatic Research: Liver-fat models, hepatic lipid metabolism, glucagon-related energy pathways, and metabolic dysfunction-associated steatotic liver disease research.
- Body-Composition Research: Adipose-tissue signaling, weight-regulation models, appetite-related pathways, and lean/fat mass research.
- Cardiometabolic Research: Lipid metabolism, blood-pressure-related markers, cholesterol dynamics, inflammatory-response pathways, and systemic metabolic resilience.
Mechanism-Based Research Interest
Retatrutide is studied because it combines three complementary metabolic receptor pathways:
- GLP-1 receptor signaling
- GIP receptor signaling
- Glucagon receptor signaling
- Insulin-response pathways
- Energy-expenditure models
- Lipid-metabolism research
- Hepatic metabolic signaling
- Integrated endocrine communication
This triple-pathway design makes retatrutide a valuable research compound for studying complex metabolic regulation, especially where glucose handling, lipid metabolism, energy balance, and hormone signaling overlap.
Investigational Research Context
Retatrutide should be considered an investigational research compound. Available research includes laboratory, preclinical, and clinical-context studies, but findings should not be interpreted as approved therapeutic outcomes.
This product is supplied for laboratory research only and is not intended for human consumption, clinical use, veterinary use, or self-experimentation.
Scientific References
View References
- Coskun T. et al. (2022) — LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept.
- Urva S. et al. (2022) — LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b randomized multiple-ascending-dose trial.
- Jastreboff A.M. et al. (2023) — Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial.
- Rosenstock J. et al. (2023) — Retatrutide, a GIP, GLP-1, and glucagon receptor agonist, for people with type 2 diabetes: a randomized phase 2 trial.
- Sanyal A.J. et al. (2024) — Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
- Katsi V. et al. (2025) — Retatrutide: A game changer in obesity pharmacotherapy.
Need Help?
